The stock last traded at $10.36 slightly over $7.46, the 50 day moving average and just a bit higher than the 200 day moving average of $7.33. The 50 day moving average went up by +38.86% and the 200 day average went up $3.03 or +41.24%. 348K shares changed hands on Thursday. Volume was up 371.47% over the stocks average daily volume.
Traders are feeling more bearish on shares of the company recently if you evaluate the increase in short interest. The company recorded a rise in short interest between June 15, 2017 and May 31, 2017 of 0.21%. Short shares increased from 2,077,417 to 2,081,787 over that period. The short-interest ratio decreased to 26.5 and the percentage of shorted shares was 0.04% on May 31.
ChemoCentryx, Inc. (NASDAQ:CCXI) has been the object of insider selling activity recently. Petrus Bekker, Chief Medical Officer sold $184,856 worth of shares at a price of $9.30 on Mon the 10th. That brings the Chief Medical Officer’s holdings to $556,503 as reported to the SEC. Petrus Bekker, Chief Medical Officer reported the sale of 65,509 shares of (CCXI). The shares sold for $9.16. Bekker now owns $548,125 of the stock according to the SEC filing.
Roger C. Lucas, Director disclosed the sale of 4,000 shares. The shares were sold on May 1st for an average price of $7.31. The Director now owns $459,229 of the stock per the Form 4 SEC filing.
Here are some other firms who have updated their holdings. As of the end of the quarter Bank Of Montreal /can/ had disposed of a total of 26,562 shares trimming its position 82.9%. The value in dollars decreased from $144,000 to $51,000 a change of $93,000 since the last quarter. As of quarter end Goldman Sachs Group Inc had bought 20,955 shares growing its stake by 35.9%. The value of the investment in CCXI went from $432,000 to $577,000 a change of 33.6% for the reporting period.
As of quarter end Bvf Inc/il had bought 192,000 shares growing its stake by 2.5%. The value of the company’s investment in ChemoCentryx, Inc. increased from $57,709,000 to $58,171,000 a change of 0.8% quarter to quarter. Nantahala Capital Management, LLC grew its position by buying 137,898 shares an increase of 29.5% in the quarter. Nantahala Capital Management, LLC owns 605,353 shares worth $4,407,000. The value of the position overall is up by 27.4%.
Equity analyst JP Morgan raised the price target and upgraded the stock on May 18 changing the price objective from $7.00 to $14.00 and moving the rating from “Neutral” to “Overweight”. On May 18 the company was upgraded from “Neutral” to “Overweight” with a current price target of $14.00 by analysts at JP Morgan.
In the market the company is trading up by 5.18 percent from yesterday’s close. As of the latest earnings report the EPS was $-0.65 and is expected to be $-0.69 for the current year with 48,173,000 shares currently outstanding. Next quarter’s EPS is forecasted to be $-0.20 and the next full year EPS is anticipated to be $-0.87.
ChemoCentryx, Inc., launched on November 8, 1996, is a biopharmaceutical company. The Company is involved in developing new medications targeted at inflammatory disorders, autoimmune diseases and cancer. Each of the Business’s drug candidates focuses on a specific chemoattractant receptor that selectively blocks its negative inflammatory or suppressive response, leaving the rest of the immune system intact. The Business’s drug candidates are small molecules, which are orally administered. The Business’s late stage compounds include Avacopan (CCX168) and CCX140. Avacopan (CCX168) is an orally administered complement inhibitor targeting the C5a receptor (C5aR), and is being developed for orphan and rare diseases, including anti-neutrophil cytoplasmic auto-antibody associated vasculitis (AAV); atypical hemolytic uremic syndrome (aHUS), and complement 3 glomerulopathy (C3G). CCX140 is an orally administered inhibitor of the chemokine receptor known as C-C chemokine receptor type 2 (CCR2), in development for diabetic nephropathy (DN), a form of chronic kidney disease (CKD), and for focal segmental glomerulosclerosis (FSGS)..